US2022340681A1PendingUtilityA1

Dual antigen-induced bipartite functional complementation

Assignee: UNIV WUERZBURG J MAXIMILIANSPriority: Jan 13, 2012Filed: Jun 17, 2022Published: Oct 27, 2022
Est. expiryJan 13, 2032(~5.5 yrs left)· nominal 20-yr term from priority
Inventors:Gernot Stuhler
G01N 33/575G01N 33/5758A61P 3/10A61P 25/00C07K 2317/56C07K 16/32A61P 7/04C07K 2317/34C07K 16/468C07K 16/30A61P 29/00C07K 16/2863C07K 16/3061A61P 43/00A61P 19/02A61P 35/00C07K 2317/73G01N 2800/245C07K 16/2833C07K 16/2827A61P 1/04A61P 9/00A61P 37/02C07K 2317/622A61P 17/06C07K 2317/31A61P 37/06A61P 31/00A61K 2039/505C07K 16/2896A61P 37/08C07K 16/2809C07K 16/289C07K 16/3007G01N 33/574
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “A” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.

Claims

exact text as granted — not AI-modified
1 . A set of polypeptides comprising:
 a first polypeptide P1 comprising
 (i) a targeting moiety T1,
 wherein said targeting moiety T1 specifically binds to an antigen A1, and 
 
 (ii) a fragment F1 of a functional domain F, 
   wherein neither said fragment F1 by itself nor said polypeptide P1 by itself is functional with respect to the function of said domain F,   and   a second polypeptide P2 comprising
 (i) a targeting moiety T2,
 wherein said targeting moiety T2 specifically binds to an antigen A2, and 
 
 (ii) a fragment F2 of said functional domain F, 
   wherein neither said fragment F2 by itself nor said polypeptide P2 by itself is functional with respect to the function of said domain F,   wherein said antigen A1 is different from said antigen A2,   wherein said polypeptide P1 and said polypeptide P2 are not associated with each other in the absence of a substrate that has both antigens A1 and A2 at its surface, and   wherein, upon dimerization of said fragment F1 of said polypeptide P1 with said fragment F2 of said polypeptide P2, the resulting dimer is functional with respect to the function of said domain F.   
     
     
         2 .- 46 . (canceled)

Join the waitlist — get patent alerts

Track US2022340681A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.